MARLBOROUGH, Mass., Jan. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, in San Francisco. Mike Mahoney, chairman and chief executive officer, will present at approximately 5:15 p.m. PT / 8:15 p.m. ET. Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, and Kenneth Stein, M.D., senior vice president and chief medical officer, in a question-and-answer session with the host analyst.
Additionally, the company will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2024, on Wednesday, February 5, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney and Dan Brennan. The company will issue a news release announcing financial results for the fourth quarter on February 5 prior to the conference call.
A live webcast and replay for each event will be accessible at htts://investors.bostonscientific.com. The replays will be available approximately one hour following the completion of each event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
This email address is being protected from spambots. You need JavaScript enabled to view it.
Jon Monson
Investor Relations
+1 (508) 683-5450
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$95.12 |
| Daily Change: | -0.13 -0.14 |
| Daily Volume: | 6,555,199 |
| Market Cap: | US$139.830B |
March 03, 2025 January 16, 2025 January 08, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
